CR20220342A - Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6 - Google Patents
Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6Info
- Publication number
- CR20220342A CR20220342A CR20220342A CR20220342A CR20220342A CR 20220342 A CR20220342 A CR 20220342A CR 20220342 A CR20220342 A CR 20220342A CR 20220342 A CR20220342 A CR 20220342A CR 20220342 A CR20220342 A CR 20220342A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cancer therapeutics
- selective cdk4
- inhibitor cancer
- inhibitor
- cdk4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripción expone inhibidores selectivos y potentes de CDK 4/6 que muestran una inhibición ventajosa del crecimiento del cáncer, incluso a bajas concentraciones. Una clase de los inhibidores de CDK 4/6 se refiere a compuestos de pirrolopirimidinas sustituidas que tienen una porción de ácido graso y son específicamente derivados de Palbociclib de la fórmula general [2A], en donde R1 es hidrógeno, arilo, alquilo, alcoxi, cicloalquilo o heterociclilo; R2 es hidrógeno, halógeno, alquilo, acilo, cicloalquilo, alcoxi, alcoxialquilo, haloalquilo, hidroxialquilo, alquenilo, alquinilo, nitrilo o nitro; R3 es hidrógeno, halógeno, alquilo, haloalquilo, hidroxialquilo o cicloalquilo; y n es un número entero de 9 a 20. Estos compuestos pueden usarse como compuestos farmacéuticos para terapias anticancerígenas y son útiles para el tratamiento, la prevención y/o el mejoramiento del cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962948498P | 2019-12-16 | 2019-12-16 | |
| US202062966834P | 2020-01-28 | 2020-01-28 | |
| PCT/IB2020/061968 WO2021124104A1 (en) | 2019-12-16 | 2020-12-15 | Selective cdk4/6 inhibitor cancer therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220342A true CR20220342A (es) | 2023-01-23 |
Family
ID=76807265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220342A CR20220342A (es) | 2019-12-16 | 2020-12-15 | Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230044749A1 (es) |
| EP (1) | EP4077325A4 (es) |
| JP (1) | JP2023507141A (es) |
| KR (1) | KR20220113986A (es) |
| CN (1) | CN115023424A (es) |
| AU (1) | AU2020406362A1 (es) |
| BR (1) | BR112022011851A2 (es) |
| CA (1) | CA3164619A1 (es) |
| CR (1) | CR20220342A (es) |
| IL (1) | IL293932A (es) |
| MX (1) | MX2022007488A (es) |
| WO (1) | WO2021124104A1 (es) |
| ZA (1) | ZA202207448B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023007499A1 (en) * | 2021-07-28 | 2023-02-02 | Immunyx Pharma Ltd. | Compounds for neutrophil ros inhibition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162721A0 (en) * | 2002-01-22 | 2005-11-20 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones |
| CN104447743B (zh) * | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
| EP3386981B1 (en) * | 2015-12-13 | 2021-10-13 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as anti-cancer agents |
| CA3045037A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| JP7367908B2 (ja) * | 2018-04-09 | 2023-10-24 | 上海科技大学 | 標的タンパク質分解化合物、その抗腫瘍応用、その中間体および中間体の応用 |
-
2020
- 2020-12-15 EP EP20902114.6A patent/EP4077325A4/en active Pending
- 2020-12-15 KR KR1020227022840A patent/KR20220113986A/ko unknown
- 2020-12-15 US US17/785,239 patent/US20230044749A1/en active Pending
- 2020-12-15 CN CN202080090850.9A patent/CN115023424A/zh active Pending
- 2020-12-15 AU AU2020406362A patent/AU2020406362A1/en active Pending
- 2020-12-15 CA CA3164619A patent/CA3164619A1/en active Pending
- 2020-12-15 JP JP2022537045A patent/JP2023507141A/ja active Pending
- 2020-12-15 IL IL293932A patent/IL293932A/en unknown
- 2020-12-15 CR CR20220342A patent/CR20220342A/es unknown
- 2020-12-15 BR BR112022011851A patent/BR112022011851A2/pt unknown
- 2020-12-15 WO PCT/IB2020/061968 patent/WO2021124104A1/en unknown
- 2020-12-15 MX MX2022007488A patent/MX2022007488A/es unknown
-
2022
- 2022-07-05 ZA ZA2022/07448A patent/ZA202207448B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115023424A (zh) | 2022-09-06 |
| BR112022011851A2 (pt) | 2022-09-06 |
| EP4077325A4 (en) | 2023-11-15 |
| AU2020406362A1 (en) | 2022-07-07 |
| WO2021124104A1 (en) | 2021-06-24 |
| KR20220113986A (ko) | 2022-08-17 |
| JP2023507141A (ja) | 2023-02-21 |
| ZA202207448B (en) | 2023-12-20 |
| MX2022007488A (es) | 2022-08-02 |
| CA3164619A1 (en) | 2021-06-24 |
| US20230044749A1 (en) | 2023-02-09 |
| IL293932A (en) | 2022-08-01 |
| EP4077325A1 (en) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500033A1 (en) | Macrocyclic compounds and uses thereof | |
| MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
| JOP20200152A1 (ar) | مركبات حلقية كبرى لعلاج مرض | |
| MX2022014648A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. | |
| PH12017502203A1 (en) | Tyrosine kinase inhibitors | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| PH12015502028A1 (en) | Ido inhibitors | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| MX2017012730A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer. | |
| MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
| MX2018005019A (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| MX366875B (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| MX2021010916A (es) | Inhibidores rad51. | |
| MX2021016049A (es) | Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas. | |
| ZA201808562B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| MX2017012102A (es) | Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti. | |
| CR20220342A (es) | Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6 | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| MX2020010577A (es) | Derivados de morfolina como inhibidores de vps34. | |
| MX2015015290A (es) | Compuestos furanona como inhibidores de quinasa. | |
| ZA202207449B (en) | Selective cdk4/6 inhibitor cancer therapeutics |